ALFA Filings
Every announcement, straight from the exchange
Every Sun Pharmaceutical Industries annual general meeting announcement on NSE and BSE, newest first, each with its own page.
Time
9 announcements
Sun Pharmaceutical Industries Ltd published voting results for a Postal Ballot. Shareholders approved the reclassification of three promoter group members to the public category.
Sun Pharma seeks shareholder approval via postal ballot to reclassify three members of the 'Promoter Group' to the 'Public' category, effective upon requisite approval.
Sun Pharmaceutical Industries held its 34th Annual General Meeting, approving financial statements, director appointments, and a final dividend of Rs. 5 per share.
SUN PHARMA announces its 34th AGM on 31 Jul 2026 to adopt financials and declare ₹5/share dividend. Director reappointments and remuneration revisions are also on the agenda.
Sun Pharmaceutical Industries scheduled its 34th AGM for July 31, 2026. The company fixed July 7, 2026, as the record date for a ₹5 per share dividend.
Sun Pharmaceutical shareholders approved the appointment of Ms. Satyavati Berera as Independent Director via postal ballot. The five-year term is effective from May 08, 2026.
Sun Pharmaceutical Industries Limited announced the conclusion of its postal ballot. Shareholders approved resolutions regarding the ratification of Cost Auditor remuneration for FY 2025–26, alterations to the Memorandum of Association, and the re-appointment of Dr. Pawan Goenka as an Independent Director for a five-year term starting May 2026.
Sun Pharmaceutical Industries Limited has initiated a postal ballot to seek shareholder approval for the appointment of Ms. Satyavati Berera as an Independent Director. Her proposed five-year tenure begins on May 8, 2026. The voting period concludes on May 8, 2026, marking a key corporate governance update for the company.
Sun Pharmaceutical Industries Limited is conducting a postal ballot to seek shareholder approval for appointing Ms. Satyavati Berera as an Independent Director for a five-year term. The e-voting period runs from April 9 to May 8, 2026. This appointment aims to maintain gender diversity and strengthen board oversight with her financial and risk expertise.